Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 199-211

  Zoratto, Federica ^a   Rossi, Luigi ^a   Zullo, Angelo ^b   Papa, Anselmo ^a   Zaccarelli, Eleonora ^a   Tomao, Luigi ^c   Giordani, Erika ^a   Colonna, Maria ^d   Baiano, Giovanni ^e   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d Don Luigi di Liegro Hospital   (Italy)

^e SAN GIOVANNI DI DIO HOSPITAL   (Italy)

Author keywords

Bevacizumab; Biomarkers; Chemotherapy; Liver metastases; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PANITUMUMAB; PLACEBO; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MAINTENANCE CHEMOTHERAPY; METASTASIS; NEUROTOXICITY; ONCOGENE; ONCOGENE B RAF; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEINURIA; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; WOUND HEALING IMPAIRMENT;

EID: 84873887127     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S30581     Document Type: Review

References (85)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. CA Cancer J Clin. 2010;60:277-300.
2. Algire GH, Chalkley H W, Legallais FY, et al. Vascular reactions of normal and malignant tissue in vivo. Vascular reactions of mice to wound and to normal and neoplastic transplants. J Natl Cancer Inst. 1945;6: 73-85.
3. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009;24:677-685.
4. Welch S, Spithoff K, Rumble B, Maroun J; Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systemic review. Ann Oncol. 2010;21:1152-1162.
5. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527-543.
6. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5:3-10.
7. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
8. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-850.
9. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the firstline treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239-3247.
10. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-2550.
11. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with MCRC. J Clin Oncol. 2003;21: 60-65.
12. Kabbinavar F F, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J Clin Oncol. 2005;23: 3697-3704.
13. Hurwitz H, Fehrenbacher L, Novontny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
14. Giantonio BJ, Catalano PJ, Neal J, et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
15. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26: 2013-2019.
16. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26: 1830-1835.
17. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000;21:505-515.
18. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972.
19. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrowderived endothelial and hematopoietic precursor cell blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-1201.
20. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15: 102-111.
21. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
22. Verheul HM, Voest EE, Schlingmann RO. Are tumors angiogenesis dependent? J Pathol. 2004;202:5-13.
23. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156:1363-1380.
24. Padera T P, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumor vessels. Nature. 2004;427:Abstract 695.
25. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420: 860-867.
26. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
27. Plouët J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J. 1989;8:3801-3806.
28. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380.
29. Melder RJ, Koening GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2:992-997.
30. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.
31. Macedo LT, Lima A, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer. 2012;12:89.
32. Stathopoulos G P, Batziou C, Trafalis D, et al. Treatment of colorectal cancer with and without bevacizumab: a Phase III study. Oncology. 2010;78:376-381.
33. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779-4786.
34. Sobrero A, Ackland S, Clark S, et al; AVIRI Trial investigators. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncolog y. 2009;77:113-119.
35. Kopetz S, Hoff PM, Morris JS, et al; AVIRI Trial investigators. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenetic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453-459.
36. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
37. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidines regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer. Results of the TREE Study. J Clin Oncol. 2008;26:3523-3529.
38. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab and mitomycin in first line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized Phase III MAX study. J Clin Oncol. 2010;28:3191-3198.
39. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12:356-361.
40. Morikawi T, Bando H, Takashima A, et al. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med Oncol. December 31, 2011. [Epub ahead of print.]
41. Yildiz R, Buyukberber S, Uner A, et al. Bevacizumab plus irinotecanbased therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest. 2010;28:33-37.
42. Horita Y, Yamada Y, Kato K, et al. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. Int J Clin Oncol. October 15, 2011. [Epub ahead of print.]
43. Mishima H, Oba K, Sakamoto J, et al. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized Phase III Study (EAGLE Study). Jpn J Clin Oncol. 2012;42:134-138.
44. Bennouna J, Borg C, Delord J P, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer. 2012;11:38-44.
45. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluoropyrimidines and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006;24:3354-3360.
46. Park LC, Lee HS, Shin SH, et al. Bevacizumab as a secondor later-line of treatment for metastatic colorectal cancer. World J Gastroenterol. 2012;18:1104-1109.
47. Lievre A, Samalin E, Mitry E, et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer. 2009;9:347.
48. Kang B W, Kim T W, Lee JL, et al. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol. 2009;26: 32-37.
49. Kwon HC, Oh S Y, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235.
50. Van Cutsem E, Rivera F, Berry S, et al; First BEAT Investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842-1847.
51. Bouganim N, Kavan M, Eid M, Metrakos P, Chaudhury P, Batist G. Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study. J Clin Oncol. 2009;27:15S Suppl:e15027.
52. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26: 5344-5351.
53. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as firstline treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845-852.
54. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for up-front resection. Ann Oncol. 2011;22:2042-2048.
55. Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and randomized Phase-III NO16966 trial. Br J Cancer. 2009;101:1033-1038.
56. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761-2767.
57. Klinger M, Tamandl D, Eipeldauer S, et al. Bevacizumab improves pathologic response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010;17:2059-2065.
58. Chibaudel B, Tournigand C, André T, De Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75-89.
59. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326-5334.
60. Andre T, Vieitez JM, Bouche O, et al. Bevacizumab plus chemotherapy beyond first progression in metastatic colorectal cancer patients previously treated with bevacizumab-based therapy: TML study subgroup findings. Ann Oncol. 2012;23 Suppl 4:Abstract O-0020.
61. Van Cutsem E, Vieitez JM, Bouche O, et al. Randomised phase III study of bevacizumab plus chemotherapy beyond progression in bevacizumab-treated patients with metastatic colorectal cancer: TML study KRAS subgroup findings. Ann Oncol. 2012;23 Suppl 4: Abstract O-0021.
62. Grothey A, Hart L, Rowland K, et al. Intermittent oxaliplatin administration improves time to-treatment failure in metastatic colorectal cancer: final results of the Phase III of the CONcePT Trial. J Clin Oncol. 2008;26 Suppl:Abstract 4010.
63. Díaz-Rubio E, Gómez-España A, Massutí B, et al; Spanish Cooperative Group for the Treatment of Digestive Tumors. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the Phase III MACRO TTD study. Oncologist. 2012;17:15-25.
64. Tournigand C, Samson B, Scheithauer W, et al. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM Phase III trial. J Clin Oncol. 2012; 30 Suppl:Abstract LBA3500.
65. Johnsson A, Frodin J, Berglund A et al. A randomized phase III trial on maintenance treatment with Bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC). J Clin Oncol. 2011;29 (Suppl.); abstract 3526.
66. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf and p-53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981-989.
67. Ahnen DJ, Feigl P, Quan G, et al. K-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer. A Southwest Oncology Group Study. Cancer Res. 1998;58:1149-1158.
68. Lievre A, Bachet JB, Boige V, et al. KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379.
69. Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. 2006;62:1931-1934.
70. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007;13: 5670-5674.
71. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of KRAS mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009;14:22-28.
72. Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol. 2011;29: 2675-2682.
73. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360: 563-570.
74. Hecht JR, Mitchell E, Chidiac T, et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-680.
75. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000;6:3739-3747.
76. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer. 2001;85:584-589.
77. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized Phase II trial of cetuximab, bevacizumab and irinotecan compared with cetuximab and bevacizumab alone in irinotecan refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25:4557-4561.
78. Kozloff M F, Sugrue M, Purdie DM, et al. Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from BRiTE observational cohort study. J Clin Oncol. 2008;26(15S):Abstract 4026.
79. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar F F, Hurwitz HI, Rohr U P. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010;136:737-743.
80. Kabbinavar F, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil based line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized trials. J Clin Oncol. 2009;27:199-205.
81. Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol. 2009;16:35-41.
82. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96-106.
83. Chong G, Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol. 2005;23:9063-9066.
84. Klinger M, Eipeldauer S, Hacker B, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;35:515-520.
85. Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer. 2008;8:120.